Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed) | PAR 19 173

Opportunity Information: Apply for PAR 19 173

Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed) is a National Institutes of Health (NIH) discretionary grant opportunity (Funding Opportunity Number PAR 19 173) that supports early-stage, exploratory research aimed at understanding how the immune system adapts, or fails to adapt, in ways that affect dental, oral, and craniofacial (DOC) health. The central theme is immune system plasticity, meaning the immune system's capacity to dynamically shift its behavior in response to changing conditions such as injury, infection, chronic inflammation, aging, or other internal and external stresses. The FOA is looking for systematic, state-of-the-art research approaches that can reveal why immune responses sometimes protect and maintain tissue function, but other times drive persistent inflammation, tissue breakdown, and impaired healing in DOC contexts.

The scientific goal is to uncover mechanisms that govern the immune system's ability or inability to maintain its normal functional role despite perturbations. In practical terms, applicants are being asked to move beyond descriptive immunology and into mechanistic work that clarifies how immune cells and immune signaling networks transition between beneficial and harmful states over time. This includes understanding the tipping points that push tissues toward degeneration versus repair, and how those tipping points may differ across individuals, disease stages, and the lifespan. The FOA emphasizes that new knowledge from these studies should help enable the development of novel immunomodulatory strategies, with a strong interest in approaches that can be tailored to individual patients. The longer-term vision is personalized, immune-based interventions that intentionally shift the balance away from destructive, chronic inflammatory patterns and toward regenerative or pro-healing responses, improving disease management and tissue resilience.

The funding mechanism is an NIH R21, which is typically used to support innovative, high-impact exploratory projects, often where preliminary data may be limited but the concept is compelling and the approach is well justified. The announcement explicitly states "Clinical Trial Not Allowed," meaning the funded work must not include clinical trial activities as defined by NIH. This generally positions the FOA for basic, translational, preclinical, and mechanistic human-subjects research that does not test interventions in a clinical trial framework. The funding listing includes an award ceiling of $200,000, reflecting the smaller, exploratory nature of the R21 mechanism.

Eligibility is broad and includes many kinds of U.S. organizations and governmental entities, such as state governments, county and city or township governments, special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, and federally recognized Native American tribal governments. It also includes public housing authorities/Indian housing authorities, Native American tribal organizations that are not federally recognized tribal governments, nonprofit organizations with and without 501(c)(3) status (other than institutions of higher education), for-profit organizations other than small businesses, and small businesses. The FOA further highlights additional eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible agencies of the federal government, regional organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations). This breadth suggests NIH is encouraging diverse institutional participation, including organizations that can bring unique community connections, specialized scientific capacity, or population-specific insights relevant to DOC health disparities and patient variability.

From an administrative standpoint, the opportunity falls under the Health funding activity category and lists CFDA numbers 93.121 and 93.846. The source data notes an original closing date of 2022-05-07 and a creation date of 2019-01-29. While those dates indicate the specific posting timeline captured in the source, the core summary of the FOA is that it funds innovative mechanistic research on immune plasticity as a driver of tissue robustness and disease outcomes in dental, oral, and craniofacial systems, with the expectation that findings will lay groundwork for future personalized immunomodulatory therapies that support regeneration and better long-term management across the lifespan.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.846.
• This funding opportunity was created on 2019-01-29.
• Applicants must submit their applications by 2022-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $200,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 19 173

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: